CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Scientists discover how snakes stand upright without limbs
April 3, 2026
Smithsonian magazine highlights a study co-authored by UC Professor Bruce Jayne, an expert in snake locomotion, about how snakes stand upright without arms or legs.
On track: Hoffman Honors Scholar studies public transit
April 2, 2026
Public transit is where Zane Sawyer’s lifelong passion for travel meets his commitment to making an impact. The University of Cincinnati first-year geography major in the College of Arts & Sciences and member of the second cohort of Hoffman Honors Scholars (HHS) has hit the ground running, designing a research project intended to capture both how public transit works and how its users perceive it.
UC design student works with sports greats in co-op
April 2, 2026
Spectrum News profiles UC College of Design, Architecture, Art, and Planning communication design student Jayden Balwally, who had an internship with the Oklahoma City Thunder and worked with the Heisman Trophy Trust and the College Football Playoff.